Report cover image

Viral Vector & Plasmid DNA Manufacturing Market by Cell Line (In-vitro, In-Vivo), Type (Adeno-Associated Virus, Adenovirus, Lentivirus), Transfection, Indication, Workflow, Application, End User - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 193 Pages
SKU # IRE18312990

Description

Viral Vector & Plasmid DNA Manufacturing Market by Cell Line (In-vitro, In-Vivo), Type (Adeno-Associated Virus, Adenovirus, Lentivirus), Transfection, Indication, Workflow, Application, End User - Global Forecast 2023-2030


The Viral Vector & Plasmid DNA Manufacturing Market is projected to reach USD 7.32 billion by 2030 from USD 1.20 billion in 2022, at a CAGR of 25.30% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Viral Vector & Plasmid DNA Manufacturing Market.
  • Based on Cell Line, market is studied across In-vitro and In-Vivo. The In-vitro commanded largest market share of 88.92% in 2022, followed by In-Vivo.
  • Based on Type, market is studied across Adeno-Associated Virus, Adenovirus, Lentivirus, and Plasmid DNA. The Lentivirus commanded largest market share of 34.21% in 2022, followed by Adeno-Associated Virus.
  • Based on Transfection, market is studied across Stable Transfection and Transient Transfection. The Stable Transfection commanded largest market share of 60.06% in 2022, followed by Transient Transfection.
  • Based on Indication, market is studied across Cancer, Genetic Disorder, and Infectious Disease. The Cancer commanded largest market share of 38.62% in 2022, followed by Infectious Disease.
  • Based on Workflow, market is studied across Downstream Processing and Upstream Processing. The Downstream Processing is further studied across Fill-finish and Purification. The Upstream Processing is further studied across Vector Amplification & Expansion and Vector Recovery/Harvesting. The Downstream Processing commanded largest market share of 55.34% in 2022, followed by Upstream Processing.
  • Based on Application, market is studied across Antisense & RNAi, Cell Therapy, Gene Therapy, and Vaccinology. The Cell Therapy commanded largest market share of 34.74% in 2022, followed by Gene Therapy.
  • Based on End User, market is studied across Biotech Companies and Research Institutes. The Biotech Companies commanded largest market share of 81.22% in 2022, followed by Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 40.00% in 2022, followed by Americas.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Viral Vector & Plasmid DNA Manufacturing Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Viral Vector & Plasmid DNA Manufacturing Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Viral Vector & Plasmid DNA Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Advanced BioScience Laboratories, Inc., Avid Bioservices, Inc., Batavia Biosciences B.V., BioNTech IMFS GmbH, Biovian Oy, c-LEcta GmbH, Cevec Pharmaceuticals GmbH, Charles River Laboratories International, Inc., Creative Biogene, FinVector, FUJIFILM Diosynth Biotechnologies Inc., GE Healthcare, GeneOne Life Science, Inc., Genezen Laboratories, Inc., Kaneka Eurogentec S.A., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, REGENXBIO Inc., Sirion-Biotech GmbH, Spark Therapeutics, Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., uniQure N.V., and Wuxi AppTec Co., Ltd..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Viral Vector & Plasmid DNA Manufacturing Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Viral Vector & Plasmid DNA Manufacturing Market?
  3. What is the competitive strategic window for identifying opportunities in the Viral Vector & Plasmid DNA Manufacturing Market?
  4. What are the latest technology trends and regulatory frameworks in the Viral Vector & Plasmid DNA Manufacturing Market?
  5. What is the market share of the leading vendors in the Viral Vector & Plasmid DNA Manufacturing Market?
  6. Which modes and strategic moves are suitable for entering the Viral Vector & Plasmid DNA Manufacturing Market?


Please Note: PDF & Excel + Online Access - 1 Year

Table of Contents

193 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Viral Vector & Plasmid DNA Manufacturing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising use of viral vectors in several treatments such as cancer demands developments in plasmids and vectors
5.1.1.2. Awareness on the benefits of gene therapy
5.1.1.3. Increase in funding for research and development activities
5.1.2. Restraints
5.1.2.1. Limited trained professionals and the complexity of the manufacturing process
5.1.3. Opportunities
5.1.3.1. Emerging demand for synthetic genes
5.1.3.2. Approval of gene therapy products from the FDA and other governing bodies
5.1.4. Challenges
5.1.4.1. Ethical concern, logistical issues, and associated cost
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Viral Vector & Plasmid DNA Manufacturing Market, by Cell Line
6.1. Introduction
6.2. In-vitro
6.3. In-Vivo
7. Viral Vector & Plasmid DNA Manufacturing Market, by Type
7.1. Introduction
7.2. Adeno-Associated Virus
7.3. Adenovirus
7.4. Lentivirus
7.5. Plasmid DNA
8. Viral Vector & Plasmid DNA Manufacturing Market, by Transfection
8.1. Introduction
8.2. Stable Transfection
8.3. Transient Transfection
9. Viral Vector & Plasmid DNA Manufacturing Market, by Indication
9.1. Introduction
9.2. Cancer
9.3. Genetic Disorder
9.4. Infectious Disease
10. Viral Vector & Plasmid DNA Manufacturing Market, by Workflow
10.1. Introduction
10.2. Downstream Processing
10.3.1. Fill-finish
10.3.2. Purification
10.3. Upstream Processing
10.4.1. Vector Amplification & Expansion
10.4.2. Vector Recovery/Harvesting
11. Viral Vector & Plasmid DNA Manufacturing Market, by Application
11.1. Introduction
11.2. Antisense & RNAi
11.3. Cell Therapy
11.4. Gene Therapy
11.5. Vaccinology
12. Viral Vector & Plasmid DNA Manufacturing Market, by End User
12.1. Introduction
12.2. Biotech Companies
12.3. Research Institutes
13. Americas Viral Vector & Plasmid DNA Manufacturing Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.2. Market Share Analysis, By Key Player
16.3. Competitive Scenario Analysis, By Key Player
17. Competitive Portfolio
17.1. Key Company Profiles
17.1.1. Advanced BioScience Laboratories, Inc.
17.1.2. Avid Bioservices, Inc.
17.1.3. Batavia Biosciences B.V.
17.1.4. BioNTech IMFS GmbH
17.1.5. Biovian Oy
17.1.6. c-LEcta GmbH
17.1.7. Cevec Pharmaceuticals GmbH
17.1.8. Charles River Laboratories International, Inc.
17.1.9. Creative Biogene
17.1.10. FinVector
17.1.11. FUJIFILM Diosynth Biotechnologies Inc.
17.1.12. GE Healthcare
17.1.13. GeneOne Life Science, Inc.
17.1.14. Genezen Laboratories, Inc.
17.1.15. Kaneka Eurogentec S.A.
17.1.16. Lonza Group Ltd.
17.1.17. Merck KGaA
17.1.18. Miltenyi Biotec B.V. & Co. KG
17.1.19. REGENXBIO Inc.
17.1.20. Sirion-Biotech GmbH
17.1.21. Spark Therapeutics, Inc.
17.1.22. Takara Bio Inc.
17.1.23. Thermo Fisher Scientific Inc.
17.1.24. uniQure N.V.
17.1.25. Wuxi AppTec Co., Ltd.
17.2. Key Product Portfolio
18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us